| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
CA Ⅱ
Carbonic Anhydrase II (CA II) |
|---|---|
| ln Vitro |
Carbonic anhydrase inhibitor 2 is a carbonic anhydrase II (CA II) inhibitor. It specifically targets CA II, functioning as an effective inhibitor. This compound is primarily used in research applications related to the modulation of intraocular pressure (IOP). No specific IC50 value is publicly available, but its in vivo efficacy in reducing IOP is reported.
|
| ln Vivo |
In vivo, carbonic anhydrase inhibitor 2 reduces intraocular pressure (IOP) in glaucomatous rabbits. It is a CA II inhibitor that shows potential for glaucoma research. CA II is a target for antiglaucoma drugs (e.g., dorzolamide, brinzolamide).
|
| Enzyme Assay |
Recombinant human carbonic anhydrase II is expressed in E. coli and purified. The CA activity assay measures the esterase activity using 4-nitrophenyl acetate (NPA) as substrate, or the CO2 hydration activity using a stopped-flow pH indicator method. For the CO2 hydration assay: the reaction is monitored by the change in pH of a buffer as CO2 is hydrated to H2CO3. The compound is incubated with the enzyme, and the inhibition constant (Ki) is determined. No specific Ki value is reported.
|
| Cell Assay |
Human corneal endothelial cells or trabecular meshwork cells expressing CA II can be used. Cells are cultured in appropriate media (e.g., DMEM with 10% FBS). Cells are treated with carbonic anhydrase inhibitor 2 (1-100 uM) for 24-72 hours. Cell viability is assessed by MTT. Cellular CA II activity is measured in cell lysates by a CO2 hydration assay. For IOP-related studies, cells can be exposed to hypoxia or oxidative stress, and the compound's protective effects can be assessed.
|
| Animal Protocol |
In vivo efficacy studies are conducted in New Zealand white rabbits with experimentally induced glaucoma (e.g., via injection of alpha-chymotrypsin or hypertonic saline injection into aqueous veins). Carbonic anhydrase inhibitor 2 (compound 7c) is formulated in a suitable vehicle (e.g., 0.5% methylcellulose or 10% DMSO in saline) and administered orally (p.o.) or topically (eye drops) at doses of 10-100 mg/kg (or 0.5-2% solution). IOP is measured using a tonometer (e.g., Tono-Pen or applanation tonometer) at baseline and at multiple time points (0-6 hours) post-dose. Reduction in IOP compared to control indicates efficacy.
|
| ADME/Pharmacokinetics |
No specific PK data for carbonic anhydrase inhibitor 2. As a sulfonamide (C12H16N4O6S, MW 344.34), it may have properties similar to clinically used CA inhibitors: moderate oral bioavailability, plasma protein binding, and half-life of 2-4 hours. It likely distributes to ocular tissues (ciliary body) where CA II is abundant. Topical administration may reduce systemic exposure. No specific PK parameters are reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for carbonic anhydrase inhibitor 2. As a CA II inhibitor, potential on-target toxicities include metabolic acidosis and paresthesia (tingling). Sulfonamide-based CA inhibitors can also cause allergic reactions (rash, fever, Stevens-Johnson syndrome) and crystalluria. For research use, handle with standard precautions. The compound is a research reagent, not for human use.
|
| References | |
| Additional Infomation |
Carbonic anhydrase inhibitor 2 (compound 7c, CAS: 2758231-43-3) is a research tool for studying carbonic anhydrase II inhibition and its effects on intraocular pressure (IOP). CA II is a key enzyme in aqueous humor secretion in the ciliary body, making it a target for antiglaucoma therapy (e.g., dorzolamide, brinzolamide). This compound is not approved for clinical use. Molecular formula: C12H16N4O6S, MW 344.34. For research use only. References: Patent applications and drug discovery for glaucoma.
|
| Molecular Formula |
C12H16N4O6S
|
|---|---|
| Molecular Weight |
344.34
|
| Exact Mass |
344.079
|
| CAS # |
2758231-43-3
|
| PubChem CID |
163196296
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N(C1C=CC(=CC=1)S(=O)(=O)N)C(=O)NCC(=O)NCC(=O)OC
|
| InChi Key |
HYGAYYSZXIJQMB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H16N4O6S/c1-22-11(18)7-14-10(17)6-15-12(19)16-8-2-4-9(5-3-8)23(13,20)21/h2-5H,6-7H2,1H3,(H,14,17)(H2,13,20,21)(H2,15,16,19)
|
| Chemical Name |
methyl 2-[[2-[(4-sulfamoylphenyl)carbamoylamino]acetyl]amino]acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 20 mg/mL (58.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (5.81 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2 mg/mL (5.81 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 2 mg/mL (5.81 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9041 mL | 14.5205 mL | 29.0411 mL | |
| 5 mM | 0.5808 mL | 2.9041 mL | 5.8082 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9041 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
